Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
A new paradigm is emerging in the targeting of multiple disease aetiologies that collectively lead to neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease, post-stroke neurodegeneration and others. This paradigm challenges the widely held assumption that 'silver bullet' agents are superior to 'dirty drugs' when it comes to drug therapy. Accumulating evidence in the literature suggests that many neurodegenerative diseases have multiple mechanisms in their aetiologies, thus suggesting that a drug with at least two mechanisms of action targeted at multiple aetiologies of the same disease may offer more therapeutic benefit in certain disorders compared with a drug that only targets one disease aetiology. This review offers a synopsis of therapeutic strategies and novel investigative drugs developed in the authors' own and other laboratories that modulate multiple disease targets associated with neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ischemic Cell Death in Brain Neurons
Lipton, P. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.4.1431 · Cited by 3,043 · cited 2×
“Divalent Ca2+ plays an important role in neuronal cell death [31,74-76].”
BackgroundThe cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198 · cited 1×
“Therefore, the primary mechanism of action of galantamine is to increase the amount of ACh in the cholinergic system, which is attenuated in AD patients, thereby improving cognition [22,23].”
BackgroundMemantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Iron, brain ageing and neurodegenerative disorders
Zecca, L., Youdim, M. B. H., Riederer, P., Connor, J. R., & Crichton, R. R. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1537 · Cited by 1,801
Self-citationRoth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155
The efficiency of multi-target drugs: the network approach might help drug design
CSERMELY, P., AGOSTON, V, & PONGOR, S. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.02.007 · Cited by 803 · cited 1×
“Such multimechanistic drugs may be low-affinity binders that modulate a variety of targets, as detailed in the ‘network approach’ by Csermely and co-workers [15], who propose that studying the effect of drugs in the context of a network of relevant protein–protein interactions may assist drug design efforts.”
BackgroundMulticomponent therapeutics for networked systems
Keith, C. T., Borisy, A. A., & Stockwell, B. R. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1609 · Cited by 769 · cited 1×
“However, a pharmaceutical combination of several drug molecules raises many challenges, not least of which is the associated complexities of combining drug entities that have potentially different degrees of bioavailability, pharmacokinetics and metabolism [8,9].”
BackgroundMolecular mechanisms of glutamate-dependent neurodegeneration in ischemia and traumatic brain injury
Arundine, M., & Tymianski, M. (2004) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s00018-003-3319-x · Cited by 647
Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo
Kaur, D., Yantiri, F., Rajagopalan, S., Kumar, J., Mo, J. Q., Boonplueang, R., Viswanath, V., Jacobs, R., Yang, L., Beal, M. F., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00126-0 · Cited by 620
Rogers, J. T., Randall, J. D., Cahill, C. M., Eder, P. S., Huang, X., Gunshin, H., Leiter, L., McPhee, J., Sarang, S. S., Utsuki, T., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207435200 · Cited by 551 · cited 2×
“It has become increasingly clear that many (if not all) proteins that are involved in iron homeostasis contain iron-responsive elements (IREs) in the 5′ and 3′ untranslated regions (UTRs) of their mRNA, respectively, and thus their synthesis and degradation are regulated by the presence or absence of iron.”
Background
Cited by
Nachon, F., Carletti, E., Ronco, C., Trovaslet, M., Nicolet, Y., Jean, L., & Renard, P.-Y. (2013) · Biochemical Journal · doi:10.1042/bj20130013 · Cited by 478
Diverse functional roles of lipocalin-2 in the central nervous system
Jha, M. K., Lee, S., Park, D. H., Kook, H., Park, K.-G., Lee, I.-K., & Suk, K. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.12.006 · Cited by 195
Rodríguez-Rodríguez, C., Telpoukhovskaia, M., & Orvig, C. (2012) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2012.03.008 · Cited by 151
Steiner, G. Z., Yeung, A., Liu, J.-X., Camfield, D. A., Blasio, F. M. D., Pipingas, A., Scholey, A. B., Stough, C., & Chang, D. H. (2015) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-016-0989-0 · Cited by 36
Metadata
- Authors
- Van der Schyf, C. J., Gal, S., Geldenhuys, W. J., & Youdim, M. B.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2006-07-21
- Volume
- 15
- Issue
- 8
- Pages
- 873-886
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2110514041
- Cited by
- 66
- References
- 17
- FWCI
- 4.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases. https://app.cochat.ai/papers/10.1517/13543784.15.8.873
- The paper
- Van der Schyf, C. J., Gal, S., Geldenhuys, W. J., & Youdim, M. B. (2006). Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases. Expert Opinion on Investigational Drugs. https://doi.org/10.1517/13543784.15.8.873
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.